Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
<h4>Background</h4>Preoperative bevacizumab has been reported to increase postoperative complication risk following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). We sought to review our experience with preoperative bevacizumab in patients undergoing CRS...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2020-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0243252 |
| _version_ | 1818362363680653312 |
|---|---|
| author | Bradley H King Joel M Baumgartner Kaitlyn J Kelly Rebecca A Marmor Andrew M Lowy Jula Veerapong |
| author_facet | Bradley H King Joel M Baumgartner Kaitlyn J Kelly Rebecca A Marmor Andrew M Lowy Jula Veerapong |
| author_sort | Bradley H King |
| collection | DOAJ |
| description | <h4>Background</h4>Preoperative bevacizumab has been reported to increase postoperative complication risk following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). We sought to review our experience with preoperative bevacizumab in patients undergoing CRS/HIPEC for peritoneal surface malignancy.<h4>Methods</h4>This is a retrospective review of patients who received neoadjuvant systemic therapy with or without bevacizumab prior to CRS/HIPEC at a high-volume academic center from 2007-2018.<h4>Results</h4>Of 499 patients, a total of 88 patients received neoadjuvant chemotherapy alone (n = 34) or in combination with bevacizumab (n = 54) within 3 months prior to CRS/HIPEC. No differences existed in 60-day major morbidity (17.6 vs. 16.7%, p = 0.81) or 60-day mortality (0 vs. 0%) between the two cohorts, and neoadjuvant bevacizumab was not associated with increased odds of overall complications (OR 0.86, 95% CI 0.35-2.09, p = 0.73) or major morbidity (OR 0.86, 95% CI 0.24-3.00, p = 0.81). Stratifying patients by primary tumor origin and post-operative complications did not reveal any significant differences between the two treatment groups. In addition, progression-free survival (PFS) and overall survival (OS) were similar in both cohorts.<h4>Conclusions</h4>Preoperative bevacizumab is not associated with increased morbidity or mortality following CRS/HIPEC. Neoadjuvant therapy employing this biologic agent is safe and should not be a deterrent for aggressive cytoreduction with curative intent. |
| first_indexed | 2024-12-13T21:31:24Z |
| format | Article |
| id | doaj.art-adbb497aa78946c0843616d0928d0cfa |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T21:31:24Z |
| publishDate | 2020-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-adbb497aa78946c0843616d0928d0cfa2022-12-21T23:30:49ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-011512e024325210.1371/journal.pone.0243252Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.Bradley H KingJoel M BaumgartnerKaitlyn J KellyRebecca A MarmorAndrew M LowyJula Veerapong<h4>Background</h4>Preoperative bevacizumab has been reported to increase postoperative complication risk following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). We sought to review our experience with preoperative bevacizumab in patients undergoing CRS/HIPEC for peritoneal surface malignancy.<h4>Methods</h4>This is a retrospective review of patients who received neoadjuvant systemic therapy with or without bevacizumab prior to CRS/HIPEC at a high-volume academic center from 2007-2018.<h4>Results</h4>Of 499 patients, a total of 88 patients received neoadjuvant chemotherapy alone (n = 34) or in combination with bevacizumab (n = 54) within 3 months prior to CRS/HIPEC. No differences existed in 60-day major morbidity (17.6 vs. 16.7%, p = 0.81) or 60-day mortality (0 vs. 0%) between the two cohorts, and neoadjuvant bevacizumab was not associated with increased odds of overall complications (OR 0.86, 95% CI 0.35-2.09, p = 0.73) or major morbidity (OR 0.86, 95% CI 0.24-3.00, p = 0.81). Stratifying patients by primary tumor origin and post-operative complications did not reveal any significant differences between the two treatment groups. In addition, progression-free survival (PFS) and overall survival (OS) were similar in both cohorts.<h4>Conclusions</h4>Preoperative bevacizumab is not associated with increased morbidity or mortality following CRS/HIPEC. Neoadjuvant therapy employing this biologic agent is safe and should not be a deterrent for aggressive cytoreduction with curative intent.https://doi.org/10.1371/journal.pone.0243252 |
| spellingShingle | Bradley H King Joel M Baumgartner Kaitlyn J Kelly Rebecca A Marmor Andrew M Lowy Jula Veerapong Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. PLoS ONE |
| title | Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. |
| title_full | Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. |
| title_fullStr | Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. |
| title_full_unstemmed | Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. |
| title_short | Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. |
| title_sort | preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy |
| url | https://doi.org/10.1371/journal.pone.0243252 |
| work_keys_str_mv | AT bradleyhking preoperativebevacizumabdoesnotincreasecomplicationsfollowingcytoreductivesurgeryandhyperthermicintraperitonealchemotherapy AT joelmbaumgartner preoperativebevacizumabdoesnotincreasecomplicationsfollowingcytoreductivesurgeryandhyperthermicintraperitonealchemotherapy AT kaitlynjkelly preoperativebevacizumabdoesnotincreasecomplicationsfollowingcytoreductivesurgeryandhyperthermicintraperitonealchemotherapy AT rebeccaamarmor preoperativebevacizumabdoesnotincreasecomplicationsfollowingcytoreductivesurgeryandhyperthermicintraperitonealchemotherapy AT andrewmlowy preoperativebevacizumabdoesnotincreasecomplicationsfollowingcytoreductivesurgeryandhyperthermicintraperitonealchemotherapy AT julaveerapong preoperativebevacizumabdoesnotincreasecomplicationsfollowingcytoreductivesurgeryandhyperthermicintraperitonealchemotherapy |